Generic Firmagon Availability
Last updated on Apr 10, 2025.
Firmagon is a brand name of degarelix, approved by the FDA in the following formulation(s):
FIRMAGON (degarelix acetate - powder;subcutaneous)
-
Manufacturer: FERRING
Approval date: December 24, 2008
Strength(s): EQ 80MG BASE/VIAL [RLD], EQ 120MG BASE/VIAL [RLD]
Is there a generic version of Firmagon available?
No. There is currently no therapeutically equivalent version of Firmagon available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Firmagon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method of treating prostate cancer with GnRH antagonist
Patent 10,695,398
Issued: June 30, 2020
Inventor(s): van der Meulen Egbert A. & Tanko Laszlo Balazs
Assignee(s): Ferring B.V.The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Patent expiration dates:
- April 27, 2032✓
- April 27, 2032
-
Methods of treating prostate cancer with GnRH antagonist
Patent 10,729,739
Issued: August 4, 2020
Inventor(s): Olesen Tine Kold & Persson Bo-Eric & Cantor Per & van der Meulen Egbert A & Jensen Jens-Kristian Slott
Assignee(s): Ferring B.V.The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Patent expiration dates:
- February 10, 2029✓
- February 10, 2029
-
Methods of treating prostate cancer with GnRH antagonist
Patent 10,973,870
Issued: April 13, 2021
Inventor(s): Olesen; Tine Kold et al.
Assignee(s): Ferring B.V. (Hoofddorp, NL)The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Patent expiration dates:
- February 10, 2029✓
- February 10, 2029
-
Method of treating prostate cancer with GnRH antagonist
Patent 11,766,468
Issued: September 26, 2023
Inventor(s): van der Meulen; Egbert A. et al.
Assignee(s): Ferring B.V. (Hoofddorp, NL)The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Patent expiration dates:
- April 27, 2032✓
- April 27, 2032
-
Method of treating prostate cancer with GnRH antagonist
Patent 11,826,397
Issued: November 28, 2023
Inventor(s): van der Meulen; Egbert A. et al.
Assignee(s): Ferring B.V. (Hoofddorp, NL)The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Patent expiration dates:
- April 27, 2032✓
- April 27, 2032
-
Method of treating prostate cancer with GnRH antagonist
Patent 9,415,085
Issued: August 16, 2016
Inventor(s): van der Meulen Egbert A. & Tankó László Balázs
Assignee(s): FERRING B.V.The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Patent expiration dates:
- April 27, 2032✓
- April 27, 2032
-
Method of treating prostate cancer with GnRH antagonist
Patent 9,579,359
Issued: February 28, 2017
Inventor(s): Olesen Tine Kold & Persson Bo-Eric & Cantor Per & van der Meulen Egbert A & Jensen Jens-Kristian Slott
Assignee(s): FERRING B.V.The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Patent expiration dates:
- February 10, 2029✓
- February 10, 2029
More about Firmagon (degarelix)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (10)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: gonadotropin-releasing hormone antagonists
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.